vs
Side-by-side financial comparison of Anteris Technologies Global Corp. (AVR) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Sanara MedTech Inc. is the larger business by last-quarter revenue ($27.5M vs $310.0K, roughly 88.8× Anteris Technologies Global Corp.). Sanara MedTech Inc. runs the higher net margin — -5.9% vs -9420.0%, a 9414.1% gap on every dollar of revenue. Sanara MedTech Inc. produced more free cash flow last quarter ($3.9M vs $-18.9M).
Anteris Technologies Global Corp is a medical technology firm specializing in innovative structural heart care solutions. It develops and commercializes bioprosthetic heart valves and transcatheter intervention products, serving healthcare providers across North America, Europe, and Asia-Pacific, with core focus on cardiac surgery and interventional cardiology segments.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
AVR vs SMTI — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $310.0K | $27.5M |
| Net Profit | $-29.2M | $-1.6M |
| Gross Margin | 70.6% | 93.2% |
| Operating Margin | -9343.5% | 23.5% |
| Net Margin | -9420.0% | -5.9% |
| Revenue YoY | — | 4.6% |
| Net Profit YoY | — | 5.3% |
| EPS (diluted) | $-0.74 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $310.0K | $27.5M | ||
| Q3 25 | $429.0K | $26.3M | ||
| Q2 25 | $618.0K | $25.8M | ||
| Q1 25 | $556.0K | $23.4M | ||
| Q4 24 | — | $26.3M | ||
| Q3 24 | — | $21.7M | ||
| Q2 24 | — | $20.2M | ||
| Q1 24 | — | $18.5M |
| Q4 25 | $-29.2M | $-1.6M | ||
| Q3 25 | $-22.2M | $-30.4M | ||
| Q2 25 | $-20.8M | $-2.0M | ||
| Q1 25 | $-21.9M | $-3.5M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | $-2.9M | ||
| Q2 24 | — | $-3.5M | ||
| Q1 24 | — | $-1.8M |
| Q4 25 | 70.6% | 93.2% | ||
| Q3 25 | 71.3% | 92.9% | ||
| Q2 25 | 76.1% | 92.5% | ||
| Q1 25 | 62.8% | 92.2% | ||
| Q4 24 | — | 91.4% | ||
| Q3 24 | — | 90.8% | ||
| Q2 24 | — | 90.0% | ||
| Q1 24 | — | 89.8% |
| Q4 25 | -9343.5% | 23.5% | ||
| Q3 25 | -5190.0% | 11.2% | ||
| Q2 25 | -3379.3% | -0.1% | ||
| Q1 25 | -3917.3% | -8.9% | ||
| Q4 24 | — | 18.6% | ||
| Q3 24 | — | 3.6% | ||
| Q2 24 | — | -14.3% | ||
| Q1 24 | — | -8.3% |
| Q4 25 | -9420.0% | -5.9% | ||
| Q3 25 | -5185.1% | -115.5% | ||
| Q2 25 | -3371.2% | -7.8% | ||
| Q1 25 | -3932.4% | -15.1% | ||
| Q4 24 | — | -6.5% | ||
| Q3 24 | — | -13.2% | ||
| Q2 24 | — | -17.4% | ||
| Q1 24 | — | -9.5% |
| Q4 25 | $-0.74 | $-0.32 | ||
| Q3 25 | $-0.62 | $-3.40 | ||
| Q2 25 | $-0.58 | $-0.23 | ||
| Q1 25 | $-0.61 | $-0.41 | ||
| Q4 24 | — | $-0.18 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | — | $-0.41 | ||
| Q1 24 | — | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $16.6M |
| Total DebtLower is stronger | $22.0K | $46.0M |
| Stockholders' EquityBook value | $-93.0K | $5.9M |
| Total Assets | $23.0M | $72.9M |
| Debt / EquityLower = less leverage | — | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $16.6M | ||
| Q3 25 | — | $14.9M | ||
| Q2 25 | — | $17.0M | ||
| Q1 25 | $49.0M | $20.7M | ||
| Q4 24 | — | $15.9M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $6.2M | ||
| Q1 24 | — | $2.8M |
| Q4 25 | $22.0K | $46.0M | ||
| Q3 25 | $26.0K | $45.1M | ||
| Q2 25 | $30.0K | $44.2M | ||
| Q1 25 | $30.0K | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $-93.0K | $5.9M | ||
| Q3 25 | $3.7M | $6.1M | ||
| Q2 25 | $24.4M | $35.4M | ||
| Q1 25 | $43.3M | $36.7M | ||
| Q4 24 | — | $39.4M | ||
| Q3 24 | — | $39.8M | ||
| Q2 24 | — | $41.7M | ||
| Q1 24 | — | $43.3M |
| Q4 25 | $23.0M | $72.9M | ||
| Q3 25 | $19.1M | $71.1M | ||
| Q2 25 | $39.9M | $98.8M | ||
| Q1 25 | $58.8M | $96.4M | ||
| Q4 24 | — | $88.1M | ||
| Q3 24 | — | $88.5M | ||
| Q2 24 | — | $73.4M | ||
| Q1 24 | — | $70.9M |
| Q4 25 | — | 7.74× | ||
| Q3 25 | 0.01× | 7.33× | ||
| Q2 25 | 0.00× | 1.25× | ||
| Q1 25 | 0.00× | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.5M | $3.9M |
| Free Cash FlowOCF − Capex | $-18.9M | $3.9M |
| FCF MarginFCF / Revenue | -6104.5% | 14.0% |
| Capex IntensityCapex / Revenue | 128.1% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-79.8M | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.5M | $3.9M | ||
| Q3 25 | $-18.3M | $2.2M | ||
| Q2 25 | $-19.5M | $2.7M | ||
| Q1 25 | $-21.5M | $-2.0M | ||
| Q4 24 | — | $932.0K | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | — | $-1.4M | ||
| Q1 24 | — | $-1.6M |
| Q4 25 | $-18.9M | $3.9M | ||
| Q3 25 | $-19.0M | $1.1M | ||
| Q2 25 | $-20.1M | $902.7K | ||
| Q1 25 | $-21.7M | $-3.7M | ||
| Q4 24 | — | $859.9K | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | -6104.5% | 14.0% | ||
| Q3 25 | -4434.5% | 4.2% | ||
| Q2 25 | -3247.9% | 3.5% | ||
| Q1 25 | -3909.5% | -15.9% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 9.4% | ||
| Q2 24 | — | -7.3% | ||
| Q1 24 | — | -9.0% |
| Q4 25 | 128.1% | 0.3% | ||
| Q3 25 | 180.0% | 4.0% | ||
| Q2 25 | 86.9% | 6.8% | ||
| Q1 25 | 44.6% | 7.4% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVR
Segment breakdown not available.
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
